Literature DB >> 6979445

Circulating antigen-antibody complexes in onchocerciasis.

M W Steward, B Sisley, C D Mackenzie, H El Sheikh.   

Abstract

The presence of circulating antigen-antibody complexes in the sera of patients with onchocerciasis was investigated using the Clq and conglutinin solid-phase binding assays. Only 50% of patients' sera had demonstrable complexes, levels of complexes were unrelated to microfilarial load and specific anti-onchocercal antibody titres and results with the two tests for complexes were not correlated. Both IgM- and IgG-containing complexes were commonly involved but there was no correlation between the levels of complexes containing these isotypes. Evidence for the presence of IgE in complexes of sera from a minority of individuals was also obtained.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979445      PMCID: PMC1536577     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Enzyme immunoassays in diagnostic medicine. Theory and practice.

Authors:  A Voller; D E Bidwell; A Bartlett
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

2.  Sympathetic ophthalmia and lymphocyte transformation.

Authors:  V G Wong; R Anderson; P J O'Brien
Journal:  Am J Ophthalmol       Date:  1971-11       Impact factor: 5.258

3.  [Epidemiological study of onchocercosis in 5 villages of the valley of the Sanaga (Cameroon)].

Authors:  C Ripert; D Riedel; R Yang; A Fouda Onana; I A Zimflou
Journal:  Bull Soc Pathol Exot Filiales       Date:  1977 Mar-Apr

4.  Intrinsically stable IgG aggregates.

Authors:  D McCarthy; D H Goddard; B K Pell; E J Holborow
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

5.  Circulating immune complexes in onchocerciasis.

Authors:  R Paganelli; J L Ngu; R J Levinsky
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

6.  Effects of various concentrations of diethylcarbamazine citrate applied as eye drops in ocular onchocerciasis, and the possibilities of improved therapy from continuous non-pulsed delivery.

Authors:  B R Jones; J Anderson; H Fuglsang
Journal:  Br J Ophthalmol       Date:  1978-07       Impact factor: 4.638

7.  Measurement of antigen-antibody complexes in mouse sera by conglutinin, C1q and rheumatoid factor solid phase binding assays.

Authors:  M E Devey; J Taylor; M W Steward
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

8.  Retinal vasculitis in rheumatoid arthritis.

Authors:  M F Martin; D G Scott; C Gilbert; P A Dieppe; D L Easty
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

9.  Retinal vasculitis: a review.

Authors:  M D Sanders
Journal:  J R Soc Med       Date:  1979-12       Impact factor: 18.000

  9 in total
  6 in total

Review 1.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

2.  Ocular manifestations of onchocerciasis in a rain forest area of west Africa.

Authors:  H S Newland; A T White; B M Greene; R P Murphy; H R Taylor
Journal:  Br J Ophthalmol       Date:  1991-03       Impact factor: 4.638

3.  Dirofilaria immitis: detection of parasite-specific antigen by monoclonal antibodies in glomerulonephritis in infected dogs.

Authors:  K Nakagaki; S Nogami; Y Hayashi; B Hammerberg; H Tanaka; I Ohishi
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

4.  Non-specific suppression of antigen-induced lymphocyte blastogenesis in Onchocerca volvulus infection in man.

Authors:  B M Greene; M M Fanning; J J Ellner
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

Review 5.  Clinical and laboratory aspects of filariasis.

Authors:  J Nanduri; J W Kazura
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

6.  Demonstration of Toxoplasma antigen containing complexes in active toxoplasmosis.

Authors:  F van Knapen; S O Panggabean; J van Leusden
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.